Finance

Lists
SGMT:NASDAQ
Sagimet Biosciences Inc
$10.21
-0.39%
(-0.040) 1D
$10.21
0.00% (0.00)
After hours
Closed: Aug 24, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGMT...
Open
$10.13
High
$10.50
Low
$9.95
Mkt. cap
634.64M
Avg. vol.
1.21M
Volume
0.00
52-wk high
$11.15
52-wk low
$4.50
EPS
-$1.28
Beta
3.37
Shares outstanding
61.59M
No. of employees
16
Open
$10.13
High
$10.50
Low
$9.95
Mkt. cap
634.64M
Avg. vol.
1.21M
Volume
0.00
52-wk high
$11.15
52-wk low
$4.50
EPS
-$1.28
Beta
3.37
Shares outstanding
61.59M
No. of employees
16
About Sagimet Biosciences Inc
CEO-
Employees16
Founded2006
HeadquartersSan Mateo, California, United States
SectorBiotechnology
Websitesagimet.com
Analyst ratings
Based on 6 analysts giving stock ratings to SGMT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for SGMT in the last 3 months.
Highest
Current $10.21
$56.00 (+448.48%)
Average
$33.67 (+229.77%)
Lowest
$25.00 (+144.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jay Olson
Oppenheimer
Buy
Maintained
$33.00
+223.2%
08/12/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
$56.00
+448.5%
08/11/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$25.00
+144.9%
08/12/2026
Yun Zhong
Wedbush
Buy
Maintained
$28.00
+174.2%
08/11/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$29.00
+184%
08/11/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$31.00
+203.6%
07/21/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$12.00
+17.5%
05/19/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$28.00
+174.2%
05/13/2026
Ritu Baral
TD Cowen
Buy
Maintained
$21.00
+105.7%
05/12/2026
Eliana Merle
Barclays
Hold
Maintained
$8.00
-21.6%
04/02/2026
Unknown Analyst
Rodman & Renshaw
Buy
Initiated
$28.00
+174.2%
03/26/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$28.00
+174.2%
03/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9.73M
6.73M
7.00M
11.54M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.60M
4.03M
4.72M
4.28M
Operating expense
14.33M
10.76M
11.71M
15.82M
Total operating expenses
14.33M
10.76M
11.71M
15.82M
Operating income
-14.33M
-10.76M
-11.71M
-15.82M
Other non operating income
-
-
-
-
EBT including unusual items
-12.91M
-9.57M
-10.65M
-13.95M
EBT excluding unusual items
-12.91M
-9.57M
-10.65M
-13.95M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.91M
-9.57M
-10.65M
-13.95M
Net profit margin
-
-
-
-
Earnings per share
-0.40
-0.29
-0.33
-0.26
Interest and investment income
1.43M
1.20M
1.06M
1.86M
Interest expense
-
-
-
-
Net interest expenses
1.43M
1.20M
1.06M
1.86M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps